Artificial Intelligence

Lumen Technologies is overhauling its balance sheet. Is this a savvy move for AI dominance or a risky gamble for the recovering telecom giant?

With a fresh $62M in funding, WELLSTAR is accelerating its AI and acquisition strategy ahead of a planned 2026 spinout, aiming to rewire Canadian healthcare.

How does a MedTech firm win 'Top Workplace' twice? Echosens proves that a mission-driven culture is the ultimate catalyst for innovation and market leadership.

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.

A new $4.2 billion coastal city in Muscat aims to merge luxury living with a digital economy. Can Oman's 'MAD' project redefine real estate and its future?

Bowman Consulting's acquisition of RPT Alliance is a strategic move to solve the energy crisis facing AI and data centers with rapid-deployment power.

AsymBio's massive Shanghai facility isn't just about capacity; it's a key move in the high-stakes world of advanced biologic drug production.

New data shows Ascentage Pharma's drug achieves responses where a leading therapy fails, signaling a strategic coup in the high-stakes oncology market.

New 52-week data shows Protagonist and Takeda's drug slashes phlebotomy needs, signaling a major shift in quality of life for polycythemia vera patients.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.

A 209kg opium seizure reveals how Canada's billion-dollar investment in AI and intelligence is disrupting sophisticated global drug smuggling networks.

Boston-based 1910 Genetics unveils an AI model that bypasses decades-old barriers, opening a vast new frontier for treating Alzheimer's and Parkinson's.

A legal fight over attorney fees in the Hess-Chevron deal reveals a costly risk in M&A. Here's why healthcare execs and investors should pay attention.

The G7 has unveiled a new blueprint for the future of work, balancing AI innovation with a major push for inclusive employment. What does it mean?

Seegene expands to France's lucrative diagnostics market, but the real story is its plan to build an automated, data-driven health intelligence network.

As Bitcoin stands firm against a weak altcoin market, the focus shifts to infrastructure. How are staking platforms building trust through security and transparency?

New long-term data suggests zorevunersen may modify Dravet syndrome, not just treat it. A look at the science, the strategy, and the stakes.

After its RELYVRIO setback, Amylyx's next-gen ALS drug AMX0114 clears a key safety hurdle. Is this the strategic pivot investors have been waiting for?

A landmark government scheme is injecting billions into innovation. Can venture capitalists like Beyond Ventures turn this capital into a tech and health boom?

New data on RAP-219 reveals more than just seizure control; it shows a strategic play to redefine treatment and capture the neurology market.